154 related articles for article (PubMed ID: 20733272)
1. Is repeat transurethral resection effective and necessary in patients with T1 bladder carcinoma?
Yucel M; Hatipoglu NK; Atakanli C; Yalcinkaya S; Dedekarginoglu G; Saracoglu U; Aras E
Urol Int; 2010; 85(3):276-80. PubMed ID: 20733272
[TBL] [Abstract][Full Text] [Related]
2. [Repeat transurethral resection for non-muscle invasive bladder cancer].
Shen YJ; Ye DW; Yao XD; Zhang SL; Dai B; Zhu YP; Zhang HL; Zhu Y; Shi GH; Ma CG
Zhonghua Wai Ke Za Zhi; 2009 May; 47(10):725-7. PubMed ID: 19615201
[TBL] [Abstract][Full Text] [Related]
3. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
4. Management of superficial bladder carcinoma: time to rethink the treatment strategies in the era of orthotopic neo-bladder.
Singh PB; Kumar A; Das SK; Pandey AK; Sharma GK; Samir Swain HB; Trivedi S; Dwivedi US
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):881-5. PubMed ID: 20814125
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of conservative therapy with transurethral resection for patients with invasive bladder cancer who cannot tolerate cystectomy.
Akamatsu S; Kanamaru S; Takenawa J; Soeda A
Hinyokika Kiyo; 2007 Dec; 53(12):863-8. PubMed ID: 18203523
[TBL] [Abstract][Full Text] [Related]
6. The value of a second transurethral resection for T1 bladder cancer.
Schwaibold HE; Sivalingam S; May F; Hartung R
BJU Int; 2006 Jun; 97(6):1199-201. PubMed ID: 16566814
[TBL] [Abstract][Full Text] [Related]
7. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma.
Li LY; Yang M; Zhang HB; Su XK; Xu WF; Chen Y; Shen ZJ; Gao X
BJU Int; 2008 Aug; 102(5):566-71. PubMed ID: 18410436
[TBL] [Abstract][Full Text] [Related]
8. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
[TBL] [Abstract][Full Text] [Related]
9. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
10. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
Daniltchenko DI; Riedl CR; Sachs MD; Koenig F; Daha KL; Pflueger H; Loening SA; Schnorr D
J Urol; 2005 Dec; 174(6):2129-33, discussion 2133. PubMed ID: 16280742
[TBL] [Abstract][Full Text] [Related]
11. A second-look TUR in T1 transitional cell carcinoma: why?
Jakse G; Algaba F; Malmström PU; Oosterlinck W
Eur Urol; 2004 May; 45(5):539-46; discussion 546. PubMed ID: 15082193
[TBL] [Abstract][Full Text] [Related]
12. Is T1G3 bladder cancer having a definite muscle layer in TUR specimens a highly progressive disease?
Shindo T; Masumori N; Fukuta F; Miyamoto S; Tsukamoto T
Jpn J Clin Oncol; 2010 Feb; 40(2):153-6. PubMed ID: 19841100
[TBL] [Abstract][Full Text] [Related]
13. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?
Divrik T; Yildirim U; Eroğlu AS; Zorlu F; Ozen H
J Urol; 2006 Apr; 175(4):1258-61. PubMed ID: 16515974
[TBL] [Abstract][Full Text] [Related]
14. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
Denzinger S; Otto W; Fritsche HM; Roessler W; Wieland WF; Hartmann A; Burger M
Int J Urol; 2007 Nov; 14(11):995-9; discussion 999. PubMed ID: 17956523
[TBL] [Abstract][Full Text] [Related]
15. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
16. A re-staging transurethral resection predicts early progression of superficial bladder cancer.
Herr HW; Donat SM
BJU Int; 2006 Jun; 97(6):1194-8. PubMed ID: 16566813
[TBL] [Abstract][Full Text] [Related]
17. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
18. Bladder preservation strategy based on combined therapy in patients with muscle-invasive bladder cancer: management and results at long-term follow-up.
Villavicencio H; Rodriguez Faba O; Palou J; Gausa L; Algaba F; Marcuello E
Urol Int; 2010; 85(3):281-6. PubMed ID: 20689253
[TBL] [Abstract][Full Text] [Related]
19. The value of a second transurethral resection in evaluating patients with bladder tumors.
Herr HW
J Urol; 1999 Jul; 162(1):74-6. PubMed ID: 10379743
[TBL] [Abstract][Full Text] [Related]
20. Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer.
Akçetin Z; Todorov J; Tüzel E; Engehausen DG; Krause FS; Sauer R; Schrott KM; Rödel C
Anticancer Res; 2005; 25(3A):1623-8. PubMed ID: 16033071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
